Hypothesis

Aged intestinal dysbiosis reduces luminal lactate production, decreasing a key metabolite that normally stabilizes HIF‑1α in bone marrow stromal cells. Lower stromal HIF‑1α diminishes secretion of erythropoietic supportive factors (e.g., SCF, CXCL12), leading to impaired EPO‑STAT5 signaling in erythroid progenitors and age‑related anemia. Restoring lactate flux from the gut should reactivate stromal HIF‑1α, rescue niche function, and improve erythropoiesis independently of CNS‑derived signals.

Mechanistic Rationale

1. Lactate as a signaling metabolite – Lactate inhibits prolyl hydroxylase domain (PHD) enzymes, preventing HIF‑1α degradation and promoting its transcriptional activity even under normoxia {4}. In the bone marrow microenvironment, HIF‑1α in mesenchymal stromal cells upregulates genes that support erythroid differentiation (SCF, VEGF, CXCL12) {2}.

2. Age‑related gut lactate deficit – With aging, Lactobacillus plantarum abundance falls and intestinal permeability rises, reducing luminal lactate that reaches the circulation {5}. Lower plasma lactate diminishes stromal HIF‑1α activation, creating a niche that is less permissive for erythropoiesis.

3. Consequences for erythropoiesis – HIF‑1α‑deficient stroma produces less SCF and CXCL12, leading to reduced retention and proliferation of erythroid progenitors. Concurrently, gut‑derived inflammatory mediators (e.g., HMGB1) further blunt EPO‑STAT5 signaling {3}. The combined effect is a synergistic block at the level of both niche support and progenitor responsiveness.

Testable Predictions

• Prediction 1: Oral supplementation with L. plantarum or lactate (e.g., sodium lactate) in aged mice will increase bone marrow interstitial lactate concentrations, elevate HIF‑1α protein in CD45‑Ter119‑ stromal cells, and restore SCF/CXCL12 expression within 2 weeks.
• Prediction 2: These changes will correlate with increased pSTAT5 levels in erythroid progenitors after ex vivo EPO stimulation and a rise in hemoglobin/hematocrit without altering circulating EPO levels.
• Prediction 3: Genetic ablation of HIF‑1α specifically in leptin‑receptor⁺ stromal cells will abolish the beneficial effects of lactate supplementation on anemia, confirming the stromal requirement.
• Falsification: If lactate supplementation fails to raise stromal HIF‑1α or improve erythrocytic indices despite correcting gut permeability and reducing systemic HMGB1, the hypothesis that gut‑derived lactate acts via stromal HIF‑1α to drive erythropoiesis is falsified.

Experimental Approach

1. Mouse models: 20‑month‑old C57BL/6 mice; groups receive (i) vehicle, (ii) L. plantarum 10⁹ CFU daily, (iii) sodium lactate 2 g/L drinking water, (iv) lactate + stromal‑specific HIF‑1α knockout (Lepr‑Cre;Hif1a^fl/fl).
2. Readouts: Plasma lactate (enzymatic assay), bone marrow lactate (microdialysis), HIF‑1α Western blot in sorted stromal cells, flow cytometry for SCF⁺/CXCL12⁺ stromal frequency, CFU‑E colonies, pSTAT5 after EPO ex vivo, peripheral hemoglobin, reticulocyte count.
3. Controls: Young mice (3 months) to baseline; antibiotic‑treated aged mice to confirm microbiota dependence.

Implications

If validated, this hypothesis shifts the geriatric anemia intervention paradigm from brain‑centric or EPO‑centric strategies to a gut‑to‑bone‑marrow axis that is modifiable by diet, probiotics, or lactate analogues. It also provides a mechanistic bridge between microbiome‑targeted longevity interventions and measurable hematopoietic outcomes, encouraging a bottom‑up design of aging therapeutics as suggested in the seed idea.